Transcriptomic signatures and repurposing drugs for COVID-19 patients: findings of bioinformatics analyses

The novel coronavirus SARS-CoV-2 is damaging the world’s social and economic fabrics seriously. Effective drugs are urgently needed to decrease the high mortality rate of COVID-19 patients. Unfortunately, effective antiviral drugs or vaccines are currently unavailable. Herein, we systematically eval...

Full description

Bibliographic Details
Main Authors: Guobing Li, Shasha Ruan, Xiaolu Zhao, Qi Liu, Yali Dou, Fengbiao Mao
Format: Article
Language:English
Published: Elsevier 2021-01-01
Series:Computational and Structural Biotechnology Journal
Online Access:http://www.sciencedirect.com/science/article/pii/S2001037020305237
id doaj-7689c3ac7ec94ebb9f06d51993558b03
record_format Article
spelling doaj-7689c3ac7ec94ebb9f06d51993558b032020-12-17T04:47:52ZengElsevierComputational and Structural Biotechnology Journal2001-03702021-01-0119115Transcriptomic signatures and repurposing drugs for COVID-19 patients: findings of bioinformatics analysesGuobing Li0Shasha Ruan1Xiaolu Zhao2Qi Liu3Yali Dou4Fengbiao Mao5Center of Basic Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing 100191, China; Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USADepartment of Clinical Oncology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, China; The First Clinical College of Wuhan University, Wuhan, Hubei 430060, ChinaCenter for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing 100191, ChinaStem Cell Program, Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USADepartment of Pathology, University of Michigan, Ann Arbor, MI 48109, USA; Corresponding authors at: Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA.Center of Basic Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing 100191, China; Corresponding authors at: Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA.The novel coronavirus SARS-CoV-2 is damaging the world’s social and economic fabrics seriously. Effective drugs are urgently needed to decrease the high mortality rate of COVID-19 patients. Unfortunately, effective antiviral drugs or vaccines are currently unavailable. Herein, we systematically evaluated the effect of SARS-CoV-2 on gene expression of both lung tissue and blood from COVID-19 patients using transcriptome profiling. Differential gene expression analysis revealed potential core mechanism of COVID-19-induced pneumonia in which IFN-α, IFN-β, IFN-γ, TNF and IL6 triggered cytokine storm mediated by neutrophil, macrophage, B and DC cells. Weighted gene correlation network analysis identified two gene modules that are highly correlated with clinical traits of COVID-19 patients, and confirmed that over-activation of immune system-mediated cytokine release syndrome is the underlying pathogenic mechanism for acute phase of COVID-19 infection. It suggested that anti-inflammatory therapies may be promising regimens for COVID-19 patients. Furthermore, drug repurposing analysis of thousands of drugs revealed that TNFα inhibitor etanercept and γ-aminobutyric acid-B receptor (GABABR) agonist baclofen showed most significant reversal power to COVID-19 gene signature, so we are highly optimistic about their clinical use for COVID-19 treatment. In addition, our results suggested that adalimumab, tocilizumab, rituximab and glucocorticoids may also have beneficial effects in restoring normal transcriptome, but not chloroquine, hydroxychloroquine or interferons. Controlled clinical trials of these candidate drugs are needed in search of effective COVID-19 treatment in current crisis.http://www.sciencedirect.com/science/article/pii/S2001037020305237
collection DOAJ
language English
format Article
sources DOAJ
author Guobing Li
Shasha Ruan
Xiaolu Zhao
Qi Liu
Yali Dou
Fengbiao Mao
spellingShingle Guobing Li
Shasha Ruan
Xiaolu Zhao
Qi Liu
Yali Dou
Fengbiao Mao
Transcriptomic signatures and repurposing drugs for COVID-19 patients: findings of bioinformatics analyses
Computational and Structural Biotechnology Journal
author_facet Guobing Li
Shasha Ruan
Xiaolu Zhao
Qi Liu
Yali Dou
Fengbiao Mao
author_sort Guobing Li
title Transcriptomic signatures and repurposing drugs for COVID-19 patients: findings of bioinformatics analyses
title_short Transcriptomic signatures and repurposing drugs for COVID-19 patients: findings of bioinformatics analyses
title_full Transcriptomic signatures and repurposing drugs for COVID-19 patients: findings of bioinformatics analyses
title_fullStr Transcriptomic signatures and repurposing drugs for COVID-19 patients: findings of bioinformatics analyses
title_full_unstemmed Transcriptomic signatures and repurposing drugs for COVID-19 patients: findings of bioinformatics analyses
title_sort transcriptomic signatures and repurposing drugs for covid-19 patients: findings of bioinformatics analyses
publisher Elsevier
series Computational and Structural Biotechnology Journal
issn 2001-0370
publishDate 2021-01-01
description The novel coronavirus SARS-CoV-2 is damaging the world’s social and economic fabrics seriously. Effective drugs are urgently needed to decrease the high mortality rate of COVID-19 patients. Unfortunately, effective antiviral drugs or vaccines are currently unavailable. Herein, we systematically evaluated the effect of SARS-CoV-2 on gene expression of both lung tissue and blood from COVID-19 patients using transcriptome profiling. Differential gene expression analysis revealed potential core mechanism of COVID-19-induced pneumonia in which IFN-α, IFN-β, IFN-γ, TNF and IL6 triggered cytokine storm mediated by neutrophil, macrophage, B and DC cells. Weighted gene correlation network analysis identified two gene modules that are highly correlated with clinical traits of COVID-19 patients, and confirmed that over-activation of immune system-mediated cytokine release syndrome is the underlying pathogenic mechanism for acute phase of COVID-19 infection. It suggested that anti-inflammatory therapies may be promising regimens for COVID-19 patients. Furthermore, drug repurposing analysis of thousands of drugs revealed that TNFα inhibitor etanercept and γ-aminobutyric acid-B receptor (GABABR) agonist baclofen showed most significant reversal power to COVID-19 gene signature, so we are highly optimistic about their clinical use for COVID-19 treatment. In addition, our results suggested that adalimumab, tocilizumab, rituximab and glucocorticoids may also have beneficial effects in restoring normal transcriptome, but not chloroquine, hydroxychloroquine or interferons. Controlled clinical trials of these candidate drugs are needed in search of effective COVID-19 treatment in current crisis.
url http://www.sciencedirect.com/science/article/pii/S2001037020305237
work_keys_str_mv AT guobingli transcriptomicsignaturesandrepurposingdrugsforcovid19patientsfindingsofbioinformaticsanalyses
AT shasharuan transcriptomicsignaturesandrepurposingdrugsforcovid19patientsfindingsofbioinformaticsanalyses
AT xiaoluzhao transcriptomicsignaturesandrepurposingdrugsforcovid19patientsfindingsofbioinformaticsanalyses
AT qiliu transcriptomicsignaturesandrepurposingdrugsforcovid19patientsfindingsofbioinformaticsanalyses
AT yalidou transcriptomicsignaturesandrepurposingdrugsforcovid19patientsfindingsofbioinformaticsanalyses
AT fengbiaomao transcriptomicsignaturesandrepurposingdrugsforcovid19patientsfindingsofbioinformaticsanalyses
_version_ 1724380437616263168